Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5323-5329

  Mangerini, Rosa ^a   Argellati, Francesca ^b   Pfeffer, Ulrich ^a   Boccardo, Francesco ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

4OH Tamoxifen; Bicalutamide; LNCaP cells; Prostate cancer; Quantitative RT PCR

Indexed keywords

ANDROGEN; ANDROSTANOLONE; B CELL LYMPHOMA 2 PROTEIN; BICALUTAMIDE; CASPASE; CYCLINE; EPIDERMAL GROWTH FACTOR; MEMBRANE PROTEIN; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; MODULATION; MYELOCYTOMATOSIS ONCOGENE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ANDROGENS; ANILIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; MALE; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAMOXIFEN; TOSYL COMPOUNDS;

EID: 84872570178     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, Conti G, Cruciani G, Dammino S, Delliponti U, Ditonno P, Ferraris V, Lilliu S, Montefiore F, Portoghese F and Spano G: Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian Prostate Cancer Project study. J Clin Oncol 17: 2027-2038, 1999.
2. Iversen P and Roder MA: The Early Prostate Cancer program: Bicalutamide in nonmetastatic prostate cancer. Expert Rev Anticancer Ther 8: 361-369, 2008.
3. Boccardo F, Rubagotti A, Conti G, Potenzoni D, Manganelli A and Del Monaco D: Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. Cancer Chemother Pharmacol 56: 415-420, 2005.
4. Bedognetti D, Rubagotti A, Conti G, Francesca F, De Cobelli O, Canclini L, Gallucci M, Aragona F, Di Tonno P, Cortellini P, Martorana G, Lapini A and Boccardo F: An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. Eur Urol 57: 238-245, 2010.
5. Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V and Montefiore F: Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 23: 808-815, 2005.
6. Boccardo F, Medicina D, Galmozzi F, Emionite L and Lo Casto M: 4-OH Tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells in vitro. Anticancer Res 25: 4277-4280, 2005.
7. Floyd MS Jr., Teahan SJ, Fitzpatrick JM and Watson RW: Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines. Prostate Cancer Prostatic Dis 12: 25-33, 2009.
8. Sobel RE and Sadar MD: Cell lines used in prostate cancer research: A compendium of old and new lines-part 1. J Urol 173: 342-359, 2005.
9. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO and Mulder E: The androgen receptor in LNCaP cells contains a mutation in the ligand-binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41: 665-669, 1992.
10. van Steenbrugge GJ, van Uffelen CJ, Bolt J and Schröder FH: The human prostatic cancer cell line LNCaP and its derived sublines: An in vitro model for the study of androgen sensitivity. J. Steroid Biochem Mol Biol 40: 207-214, 1991.
11. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS and Kozlowski JM: Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136: 796-803, 1995.
12. Alt JR, Cleveland JL, Hannink M and Diehl JA: Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14: 3102-3114, 2000.
13. Wolgemuth DJ, Lele KM, Jobanputra V and Salazar G: The A-type cyclins and the meiotic cell cycle in mammalian male germ cells. Int J Androl 4: 192-199, 2004.
14. Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev 25: 276-308, 2004.
15. Byrne RL, Leung H and Neal DE: Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br J Urol 77: 627-633, 1996.
16. Boccardo F, Rubagotti A, Battaglia M, Zattoni F, Bertaccini A, Romagnoli A and Conti G: Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. Int J Biol Markers 21: 123-126, 2006.
17. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM and Abate-Shen C: Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 99: 2884-2889, 2002.
18. Nan B, Snabboon T, Unni E, X-J Yuan, Whang YE and Marcelli M: The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol 31: 169-183, 2003.
19. Wu Z, Conaway M, Gioeli D, Weber MJ and Theodorescu D: Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells. Prostate 66: 1114-1123, 2006.
20. Guo C, Armbruster BN, Price DT and Counter CM: In vivo regulation of hTERT expression and telomerase activity by androgen. J Urol 170: 615-618, 2003.
21. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
22. Silva IS, Morsch DM, Urnauer L and Spritzer PM: Androgen-induced cell growth and c-MYC expression in human non-transformed epithelial prostatic cells in primary culture. Endocr Res 27: 153-169, 2001.
23. Bouchal J, Baumforth KR, Sváchová M, Murray PG, von Angerer E and Kolár Z: Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol 57: 83-92, 2005.
24. Nilsson UW and Dabrosin C: Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo. Cancer Res 66: 4789-4794, 2006.